Kosan drug fails prostate cancer trial
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Kosan's epothilone compound KOS-862 (epothilone D) did not meet the primary endpoint of response in a Phase II trial in hormone refractory prostate cancer, the firm says Oct. 18. The company is discontinuing the trial and focusing on an ongoing Phase II study of KOS-862 as monotherapy in metastatic breast cancer. KOS-862 inhibits cancer cells by the same mechanism as taxanes, Kosan explains. A follow-on compound to KOS-862, KOS-1584, is in Phase I. Kosan is developing its epothilones under a 2002 agreement with Roche...